FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Novo Nordisk.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Endocrinology · Type 2 Diabetes
- Sub-indication
- General
Related signal: Novo Nordisk Tests UBT251 for Type 2 Diabetes in New Clinical Trial